Actively Recruiting
OPtimizing REperfusion by Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-04-16
530
Participants Needed
1
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
PEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of intra-arterial thrombolysis as adjunct to endovascular treatment in improving 90-day functional outcome in acute ischemic stroke patients due to medium vessel occlusion (MeVO) within 24 hours of symptom onset.
CONDITIONS
Official Title
OPtimizing REperfusion by Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Clinical diagnosis of acute ischemic stroke
- CT or MR angiography confirming isolated medium vessel occlusion in specified brain arteries
- Baseline NIH Stroke Scale score of 6 or higher
- Ability to start treatment within 6 hours of last known well, or within 6 to 24 hours with evidence of salvageable brain tissue
- Signed informed consent
You will not qualify if you...
- Evidence of intracranial hemorrhage
- Pre-stroke modified Rankin Scale score of 2 or higher
- Rapidly improving symptoms likely resulting in NIHSS score below 6 at randomization
- Intervention procedure unlikely to be completed
- Suspected cerebral vasculitis, septic embolization, or infective endocarditis-related vascular occlusion
- Suspected arterial dissection
- Severe allergy to contrast agents or contraindication to iodine contrast
- Known bleeding disorders or anticoagulant factor deficiencies
- Coagulation disorder with INR above 1.7 or recent use of new oral anticoagulants
- Platelet count below 50 x 10^9/L
- Active or recent bleeding or recent major surgery or biopsy within 1 month
- Uncontrolled high blood pressure refractory to treatment
- Severe renal insufficiency or elevated blood creatinine
- Radiological evidence of mass effect or intracranial tumor (except small meningioma)
- Life expectancy less than 6 months due to advanced disease
- Women who are pregnant or breastfeeding
- Participation in other clinical trials
- Any condition making the patient unsuitable or at significant risk for the study, including psychiatric or cognitive impairments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
Z
Zhenhong Deng
CONTACT
X
Xinguang Yang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here